In a post on Truth Social, President Trump stated: “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America. “IS BUILDING” will be defined as, “breaking ground” and/or “under construction.” There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started. Thank you for your attention to this matter!” Publicly traded large pharma companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GlaxoSmithKline (GSK) Bets on Politics and U.S. Pipeline to Reclaim Pharma Prominence
- Bristol Myers commitment a reminder of Veeva’s progress, says Stifel
- CDC panel votes to end universal Covid vaccine recommendation, Bloomberg says
- GSK’s New COPD Study: A Potential Game-Changer?
- Drugmakers pledge to spend over $350B in U.S., WSJ reports